Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.

Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaaw3163. doi: 10.1126/scitranslmed.aaw3163.

PMID:
31578242
2.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.

3.

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S.

J Virol. 2018 May 29;92(12). pii: e02230-17. doi: 10.1128/JVI.02230-17. Print 2018 Jun 15.

4.

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.

Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, Gunther S, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X.

PLoS Med. 2018 Mar 27;15(3):e1002535. doi: 10.1371/journal.pmed.1002535. eCollection 2018 Mar.

5.

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW.

Sci Rep. 2017 Jun 22;7(1):4099. doi: 10.1038/s41598-017-03910-7.

6.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

7.

Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and analysis of virus populations.

Piorkowski G, Jacquot F, Quérat G, Carbonnelle C, Pannetier D, Mentré F, Raoul H, de Lamballerie X.

Antiviral Res. 2017 Apr;140:95-105. doi: 10.1016/j.antiviral.2017.01.017. Epub 2017 Jan 26.

8.

The contribution of the European high containment laboratories during the 2014-2015 Ebola Virus Disease emergency.

Nisii C, Vincenti D, Fusco FM, Schmidt-Chanasit J, Carbonnelle C, Raoul H, Eickmann M, Hewson R, Brave A, Nuncio S, Sanchez-Seco MP, Palyi B, Kis Z, Zange S, Nitsche A, Kurth A, Strasser M, Capobianchi MR, Ozin A, Guglielmetti P, Menel-Lemos C, Jacob D, Grunow R, Ippolito G, Di Caro A.

Clin Microbiol Infect. 2017 Feb;23(2):58-60. doi: 10.1016/j.cmi.2016.07.003. Epub 2016 Jul 9. No abstract available.

9.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

10.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.

11.

Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.

Herbreteau CH, Jacquot F, Rith S, Vacher L, Nguyen L, Carbonnelle C, Lotteau V, Jolivet M, Raoul H, Buchy P, Saluzzo JF.

Immunotherapy. 2014;6(6):699-708. doi: 10.2217/imt.14.40. Epub 2014 Mar 27.

12.

Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication.

Mateo M, Carbonnelle C, Martinez MJ, Reynard O, Page A, Volchkova VA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S892-6. doi: 10.1093/infdis/jir311.

PMID:
21987766
13.

VP24 is a molecular determinant of Ebola virus virulence in guinea pigs.

Mateo M, Carbonnelle C, Reynard O, Kolesnikova L, Nemirov K, Page A, Volchkova VA, Volchkov VE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1011-20. doi: 10.1093/infdis/jir338.

PMID:
21987737
14.

Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation.

Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, Volchkov VE, Nichol ST, Basler CF.

J Virol. 2006 Jun;80(11):5156-67.

15.

Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level.

Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, Ottmann M, Khromykh A, Volchkov VE.

J Gen Virol. 2006 May;87(Pt 5):1247-57.

PMID:
16603527
16.

Ectodomain shedding of the glycoprotein GP of Ebola virus.

Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, Ströher U, Klenk HD, Volchkov V.

EMBO J. 2004 May 19;23(10):2175-84. Epub 2004 Apr 22.

17.

The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro.

Fournier C, Cortay JC, Carbonnelle C, Ehresmann C, Marquet R, Boulanger P.

Virus Genes. 2002 Dec;25(3):255-69.

PMID:
12881637
18.

The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization.

Bertrand E, Castanotto D, Zhou C, Carbonnelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D, Rossi JJ.

RNA. 1997 Jan;3(1):75-88.

Supplemental Content

Loading ...
Support Center